CRISPR/Cas9 therapeutics: progress and prospects.

Li T, Yang Y, Qi H, Cui W, Zhang L, Fu X, He X, Liu M, Li PF, Yu T. · 2023

Read CRISPR/Cas9 therapeutics: progress and prospects. by Li T, Yang Y, Qi H, Cui W, Zhang L, Fu X, He X, Liu M, Li PF, Yu T. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9841506.txt.

Introduction

Li and co-authors review CRISPR and Cas9 therapeutics, weighing progress made and prospects ahead. The editing system can fix harmful base changes for good. It can also shut off disease causing genes outright. That promise makes it a hoped for tool of future medicine.

Many Cas9 variants and offshoots now serve different jobs. Base editors and RNA editors widen the reach further. The hard part is delivery to sick cells inside the body. Nonviral carriers with targeting skills draw the field's focus. Disease traits themselves may flag where carriers should go. The review sorts the field by editing type first. Delivery vectors get their own long survey next. Disease traits that guide targeting complete the frame. Trial successes so far are gathered and judged. Open safety and precision problems are stated plainly.

Catalog record

CREATORLi T, Yang Y, Qi H, Cui W, Zhang L, Fu X, He X, Liu M, Li PF, Yu T.
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE160 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC9841506

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

CRISPR/Cas9 therapeutics: progress and prospects By Tianxiang Li, Yanyan Yang, Hongzhao Qi, Weigang Cui, Lin Zhang, Xiuxiu Fu, Xiangqin He, Meixin Liu, Pei-feng Li, Tao Yu Published in: Signal Transduction and Targeted Therapy DOI: 10.1038/s41392-023-01309-7 ABSTRACT Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) gene-editing technology is the ideal tool of the future for treating diseases by permanently correcting deleterious base mutations or disrupting disease-causing genes with great precision and efficiency. A variety of efficient Cas9 variants and derivatives have been developed to cope with the complex genomic changes that occur during diseases. However, strategies to effectively deliver the CRISPR system to diseased cells in vivo are currently lacking, and nonviral vectors with target recognition functions may be the focus of future research. Pathological and physiological changes resulting from disease onset are expected to serve as identifying factors for targeted delivery or targets for gene editing. Diseases are both varied and complex, and the choice of appropriate gene-editing methods and delivery vectors for different diseases is important. Meanwhile, there are still many potential challenges identified when targeting delivery of CRISPR/Cas9 technology for disease treatment. This paper reviews the current developments in three aspects, namely, gene-editing type, delivery vector, and disease characteristics. Additionally, this paper summarizes successful examples of clinical trials and finally describes possible problems associated with current CRISPR applications. INTRODUCTION Gene editing is a technology that precisely modifies the genome sequence to induce insertions, deletions, or base substitutions in the genome.1,2 Many diseases are accompanied by changes in gene expression in vivo, particularly some genetic diseases caused by mutations in a single gene, and gene-editing technology is expected to control the occurrence of diseases at the genetic level.3 To date, gene-editing technology has undergone three main generations of development: the first generation of gene-editing technology was zinc-finger nucleases (ZFNs); the second generation was transcription activator-like effector nucleases (TALENs); and the most widely used third generation gene-editing technology is clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas).4 Unlike ZFNs and TALENs, which use proteins to target DNA strands, CRISPR technology directs Cas proteins to a specified location in the genome by changing the base sequence of a small segment of guide RNA, thus improving the efficiency of gene editing and expanding the applicability of gene-editing technology.5 CRISPR/ Cas9 is a highly effective gene-editing tool that is widely used in the scientific community.6 The CRISPR/Cas9 system evolved naturally in bacteria and archaea as a defense mechanism against phage infection and plasmid transfer.7,8 Bacteria or archaea acquire a segment of their DNA sequence to insert into the CRISPR spacer region when first infiltrated by an exogenous phage or plasmid. If reinfected with homologous DNA, the bacterium will initiate transcription of the CRISPR region. After a series of processing and maturation processes to generate a single guide RNA (sgRNA), the sgRNA guides Cas9 to shear the DNA strand that disrupts the homologous spacer region. The recognition process of the sgRNA requires the involvement of protospacer-adjacent motifs (PAMs), a short guanine-enriched sequence.9 The preferred PAM by Streptococcus pyogenes Cas9 (SpCas9) is NGG, which is common in the genomes of most organisms, thereby facilitating the use of CRISPR technology across the fields of plant and animal science, together with biomedicine.10–14 By changing the nucleotide sequence of a small segment of guide RNA, CRISPR/Cas9 allows the accurate targeting of almost any desired genomic locus for the purpose of correcting disease-causing mutations or silencing genes associated with disease onset.5,15 However, some highly chromatinized regions in the genome may not be accessible to CRISPR/Cas9. Promising applications for this technology include the treatment of cancers, cardiovascular diseases, sickle cell anemia, and neurodegenerative disease.16–19 Wild-type Cas9 only cuts double-stranded DNA to form double-strand breaks (DSBs), which are repaired through DNA repair mechanisms, namely, homology-directed repair (HDR) and nonhomologous end joining (NHEJ).20–22 The base sequence of the original gene is damaged, resulting in inactivation, but the inactivation of a single deleterious gene cannot address the complex processes of all disease events.23 Therefore, researchers searched for possible ways to modify Cas9 by elucidating the physicochemical structure of Cas9, the mechanism of action by which Cas9 cleaves double chains, and other properties. They endowed Cas9 with new functions by mutating the structural domain of Cas9 and introducing effectors, including transcriptional regulatory tools such as dead Cas9 (dCas9) effectors and single-base substitution tools such as cytosine base editors (CBEs), adenine base editors (ABEs), and prime editors (PEs). Moreover, RNA recognition and cleavage functions can be performed by Cas13a isolated from Leptotrichia shahii.24–28 These Cas9 variants and derivatives enrich the gene-editing paradigm and can be adapted to additional types of diseases. Although several experiments have documented the use of gene-editing technology to modify cells in vitro for return to the body to treat some diseases, this approach is not applicable to most disease types. Achieving stable, efficient, and safe delivery in vivo is a challenge that must be overcome before CRISPR technology becomes a common treatment modality. CRISPR systems such as plasmid DNA (pDNA), mRNA and ribonucleoproteins (RNPs) are subject to degradation and immune clearance in vivo after direct delivery and therefore require the help of delivery vectors.29 Adeno-associated virus (AAV) vectors are not suitable for application in most diseases because of the drawbacks of a limited loading capacity, a lack of specific targeting ability and inability to integrate into the host genome.30 Nonviral vectors have been a hot topic of research in recent years, where lipid nanoparticles have been used in the clinic for the delivery of CRISPR gene drugs.31 Polymeric nanoparticles, biomimetic nanomaterials, and exosomes have also shown potential for the delivery of CRISPR systems in animal experiments.32 Further research and development are needed to apply nonviral vectors to a wide range of clinical applications. Each disease has different characteristics, and our aim is not to develop a universal delivery vehicle but to develop multiple vehicles applicable to different types of diseases. Therefore, studying the pathogenesis of diseases and the pathological characteristics of disease cells and tissues and constructing environment-responsive and ligand-recognizing nanoparticles based on these characteristics will further enrich gene-targeting drugs in diseased tissues.33 In addition, exosomes and cell membranes from immune cells or diseased organs can effectively avoid immune clearance, and the abundant membrane proteins on the surface enable gene-targeting drugs to be delivered to diseased cells. In this review, we discuss the development of CRISPR technology and summarize the various types of gene-editing tools that have been developed in recent years. Delivery systems for CRISPR systems in the body are also summarized, with a focus on developing new systems more suitable for different diseases, and finally, the review addresses a collection of problems that may arise when applying CRISPR technology to treat diseases and the corresponding strategies. In conclusion, this approach has positive implications for providing the most effective gene therapy modalities for different diseases. DISCOVERY AND DEVELOPMENT OF CRISPR TECHNOLOGY CRISPR-related gene-editing technology is currently one of the hottest biological tools. Since 2013, explosive growth has been recorded in the study of CRISPR technology, with tens of thousands of CRISPR-related articles published. In October 2020, the Nobel Prize in Chemistry was awarded to French microbiologist Emmanuelle Charpentier and American biologist Jennifer Doudna for “developing a

Read the complete text